FIG 2.

(A) Distribution of responses on treatment guidelines followed before and during the COVID surge among 1,103 respondents regarding a DCIS case 1. A 52-year-old woman was diagnosed with 1.5-cm grade 2, ER+/PR+ DCIS and treated with a left lumpectomy with final surgical margins >2 mm. Adjuvant endocrine therapy was initiated. (B) Distribution of responses on treatment guidelines followed before and during the COVID surge among 1,103 respondents regarding an early-stage invasive BC after breast-conserving surgery case 2. A 61-year-old female underwent a right lumpectomy revealing a 2-cm grade 2, ER+, PR+, HER2– invasive lobular carcinoma with no evidence of lymphovascular invasion. Neither of two sentinel nodes contained malignancy. The Oncotype Dx recurrence score was 8. Endocrine therapy was initiated. ^aResponses regarding treatment recommendation are shown. BC, breast cancer; DCIS, ductal carcinoma in situ; ER+, estrogen receptor–positive; HER2–, human epidermal growth factor receptor 2–negative; PR+, progesterone receptor–positive; RT, radiation therapy.